Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisKASL clinical practice guidelines: management of chronic hepatitis BHepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawalOutcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factorsDirect acting antivirals for the treatment of chronic viral hepatitisNucleoside/nucleotide analogues in the treatment of chronic hepatitis BInhibitor-Based Therapeutics for Treatment of Viral HepatitisCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaChronic hepatitis B: Advances in treatment.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment.Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by SimpleprobeOff-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BPredictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or TenofovirRelapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients.CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting.Discontinuation of nucleoside analogues in hepatitis B virus infectionTenofovir disoproxil fumarate in the treatment of chronic hepatitis B.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?Hepatitis B therapy.Hepatitis B surface antigen monitoring and management of chronic hepatitis B.The management of chronic hepatitis B in Asian Americans.Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.Peginterferon α in the treatment of chronic hepatitis B.Current developments in nucleoside/nucleotide analogues for hepatitis B.When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.Improving clinical outcomes of chronic hepatitis B virus infection.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B.Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.
P2860
Q26740323-8ADEEAF4-60CD-48D3-8354-34708656CD81Q26752475-EE5B07D4-BE3D-4228-905F-4E4E45E4893AQ26995814-723DD7FD-7A5A-4D79-8DE1-6A2B9C0E4F6EQ27020938-4F214059-C952-491A-A17E-FA3572E0966BQ27022216-91D4BEB2-F7AB-414D-A7D2-1EE4122B3B0FQ27030828-E28147CC-FAB8-4034-BEEA-928638824F17Q28073697-6CCF25FC-D95E-47F2-BC81-380B93970CA1Q28550643-E299C86A-3903-4983-BAC1-F2CB287D0369Q33660010-421DD3AF-F53F-41A5-804F-7153A25014EEQ33926126-3BA236B5-9168-4DD9-B2E2-B1BB012881A1Q34107607-23D493C4-CA94-4C06-92D4-16F2AF5F89D3Q34137291-CFCFD594-CE5A-4B39-BC7C-B146F1A1A3EDQ34252292-C635574E-EA3A-44F2-BA5F-0CA71AEF4E63Q35097411-8CBCA10A-0F20-46E5-9E35-8D6824C40D46Q35183285-24433B89-48DF-4038-AF56-9747C7ADA3FCQ35250340-89AD3822-C8BA-4F5F-AADB-96583773742EQ35692307-B1E80EA5-44F2-4497-B6E0-775E91970B30Q35961444-9F93C784-7BF3-4713-AE79-5114043EE1A8Q36091371-FBD8EA55-B67D-4DE5-82CD-805F50B3D50FQ36189795-8C3CCFD9-9800-4FD9-9691-0DC2E3CD9035Q36255419-706D986A-2E9A-4954-9259-7A3DEFF07C67Q36410401-88A9D4F4-8EC5-444A-8C3B-3BEBE956FEB5Q36716653-245E9435-173A-4BCF-B1FA-DA497AD5B32BQ36981346-1F5E1CB0-5D8A-4C2B-A69A-DAF0FBD2A391Q37165176-D8645BAA-BC24-4821-9958-6918B9601F6EQ37343296-24252101-92AD-456A-AF88-15C31E8A9D80Q37639565-F6C4A730-C0E2-4241-BC66-64A6990E119EQ37710791-129DB3F9-483D-42B3-A310-3E03FE46FC7AQ37800919-B4D9EAFB-002A-4159-A1C4-E20EEDB67A02Q37825532-6CBDCA62-99A5-410E-81DE-166AE23B41DCQ37855531-5B9ADB70-DDD9-467C-AEBE-9314919B70BAQ37892655-5153F85F-0E99-4064-8838-02E43FD83AC5Q37936321-BCCB1C51-2691-4AE0-99EA-79415243B9AEQ38067130-FE6D2516-D340-4285-9D7B-5CAF17704B49Q38205028-1B26DA03-BBBE-4643-A831-12E97AD1B7D7Q38208628-3BD94818-5864-47E1-8A28-975C12886987Q38223364-6CA27195-4452-4E9D-BDC2-798DD2C25423Q38252962-1B77B7C1-6BA7-4FB1-B2BA-B9203C425186Q38268743-A25DD762-E318-4EF3-81D0-2A693ED431C2Q38283963-2767ABFF-C9AD-4EA8-BCFD-6B35A1460DE5
P2860
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Nucleos(t)ide analogues only i ...... ents with chronic hepatitis B.
@en
type
label
Nucleos(t)ide analogues only i ...... ents with chronic hepatitis B.
@en
prefLabel
Nucleos(t)ide analogues only i ...... ents with chronic hepatitis B.
@en
P2093
P1433
P1476
Nucleos(t)ide analogues only i ...... ents with chronic hepatitis B.
@en
P2093
Harry L A Janssen
Jurriën G P Reijnders
Moniek J Perquin
Ningping Zhang
P304
P356
10.1053/J.GASTRO.2010.03.059
P407
P50
P577
2010-04-08T00:00:00Z